- Home
- ARMN vs KALV Comparison
ARMN vs KALV Comparison
Compare ARMN & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- KALV
- Stock Information
- Founded
- ARMN 1992
- KALV N/A
- Country
- ARMN Canada
- KALV United States
- Employees
- ARMN N/A
- KALV N/A
- Industry
- ARMN
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- KALV Health Care
- Exchange
- ARMN Nasdaq
- KALV Nasdaq
- Market Cap
- ARMN 769.7M
- KALV 651.3M
- IPO Year
- ARMN N/A
- KALV N/A
- Fundamental
- Price
- ARMN $6.54
- KALV $11.80
- Analyst Decision
- ARMN
- KALV Strong Buy
- Analyst Count
- ARMN 0
- KALV 8
- Target Price
- ARMN N/A
- KALV $24.83
- AVG Volume (30 Days)
- ARMN 1.2M
- KALV 496.3K
- Earning Date
- ARMN 05-07-2025
- KALV 07-10-2025
- Dividend Yield
- ARMN N/A
- KALV N/A
- EPS Growth
- ARMN 28.55
- KALV N/A
- EPS
- ARMN 0.15
- KALV N/A
- Revenue
- ARMN $560,512,000.00
- KALV N/A
- Revenue This Year
- ARMN $49.45
- KALV N/A
- Revenue Next Year
- ARMN N/A
- KALV N/A
- P/E Ratio
- ARMN $41.94
- KALV N/A
- Revenue Growth
- ARMN 22.28
- KALV N/A
- 52 Week Low
- ARMN $3.29
- KALV $7.30
- 52 Week High
- ARMN $6.59
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- ARMN 67.43
- KALV 48.35
- Support Level
- ARMN $6.12
- KALV $11.11
- Resistance Level
- ARMN $6.59
- KALV $11.93
- Average True Range (ATR)
- ARMN 0.21
- KALV 0.54
- MACD
- ARMN 0.03
- KALV -0.04
- Stochastic Oscillator
- ARMN 95.26
- KALV 48.94
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.